Table 2 Demographic information for the ADNI dataset
From: APOE effects on regional tau in preclinical Alzheimer’s disease
FBP (Aβ+ n = 109) | FBB (Aβ+ n = 111) | Overall (Aβ+ n = 220) | |
|---|---|---|---|
Age, mean (SD) | 78.8 (7.3) | 73.1 (7.2) | 75.9 (7.8) |
Sex, n (%) | |||
Male | 54 (50%) | 55 (50%) | 109 (50%) |
Female | 55 (50%) | 56 (50%) | 111 (50%) |
Diagnosis, n (%) | |||
CU | 45 (41%) | 49 (44%) | 94 (43%) |
MCI due to AD | 57 (52%) | 59 (53%) | 116 (53%) |
MCI due to Other | 7 (6%) | 3 (3%) | 10 (5%) |
APOE genotype, n (%) | |||
e2/e2 | 0 (0%) | 0 (0%) | 0 (0%) |
e2/e3 | 8 (7%) | 1 (1%) | 9 (4%) |
e2/e4 | 3 (3%) | 1 (1%) | 4 (2%) |
e3/e3 | 39 (36%) | 35 (32%) | 74 (34%) |
e3/e4 | 46 (42%) | 58 (52%) | 104 (47%) |
e4/e4 | 13 (12%) | 16 (14%) | 29 (13%) |
Amyloid Centiloid, mean (SD) | 59.4 (30.5) | 69.2 (35.3) | 64.3 (33.3) |
Years between tau and amyloid PET scans, mean (SD) | −2.3 (1.9) | 0.0 (0.2) | −1.2 (1.8) |